CAPItello-280 Trial Aims to Confirm Findings from ProCAID Trial

At the recent ACSO-GU symposium, the design and study endpoints from the CAPItello-280 trial were presented. The trial-in-progress aims to confirm the findings made in the ProCAID study, investigating the effects and safety of adding capivasertib to docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer (CRPC).